DEA to ban synthetic cannabinoids | Behavioral Healthcare Executive Skip to content Skip to navigation

DEA to ban synthetic cannabinoids

November 29, 2010
by News release
| Reprints

The US Drug Enforcement Administration (DEA) issued a notice of intent to temporarily place five synthetic cannabinoids into the Controlled Substances Act (CSA), effective November 24, pursuant to the temporary scheduling provisions under 21 U.S.C. 811(h) of the Controlled Substances Act.

The substances are:

  • 1-pentyl-3-(1-naphthoyl)indole (JWH-018)
  • 1-butyl-3-(1-naphthoyl)indole (JWH-073)
  • 1-[2-(4-morpholinyl)ethyl]-3-(1-naphthoyl)indole (JWH-200)
  • 5-(1,1-dimethylheptyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (CP-47,497)
  • 5-(1,1-dimethyloctyl)-2-[(1R,3S)-3-hydroxycyclohexyl]-phenol (cannabicyclohexanol; CP-47,497 C8 homologue).

This intended action is based on a finding by the DEA Deputy Administrator that the placement of these synthetic cannabinoids into Schedule I of the CSA is necessary to avoid an imminent hazard to the public safety. Finalization of this action will impose criminal sanctions and regulatory controls of Schedule I substances under the CSA on the manufacture, distribution, possession, importation, and exportation of these synthetic cannabinoids.

For a copy of the complete DEA action, go to